Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance

Key Points

• Ubiquitination and deubiquitination are essential mechanisms in NSCLC drug resistance, impacting treatment outcomes.
• Key evidence indicates that altered ubiquitination pathways affect tumor growth and survival, showing significant correlation.
• Assessment using biomarker analysis across different NSCLC samples highlights the importance of these pathways.
• These findings underline the potential for targeting ubiquitination to enhance therapeutic strategies, warranting further investigation.